TOI ONCOLOGY INSTITUTE INC (THE)

The Oncology Institute Announces New Leaders to Oversee Technology and Clinical Trials

The Oncology Institute Announces New Leaders to Oversee Technology and Clinical Trials

Phil Reger and Cristina Green Will Serve as the Chief Information Officer and Vice President of Clinical Research, Respectively

CERRITOS, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, is pleased to announce the hiring of two new executives. Phil Reger will serve as the Chief Information Officer and Cristina Green will serve as the Vice President of Clinical Research.

As Chief Information Officer, a newly created position, Mr. Reger will lead enterprise-wide technology and data initiatives, developing strategies to support TOI’s growth. Mr. Reger’s professional experience includes 25 years of IT experience in high-growth environments, with 20 of them specializing in healthcare. Before joining TOI, Mr. Reger was part of the founding team that launched Radiology Partners, the largest radiology practice in the United States. As CTO, he launched and grew an IT department that met business demands for high levels of acquisitive growth, reliable clinical systems, and advanced capabilities. Most recently, he partnered with visionary clinicians and data scientists to develop an artificial intelligence platform enabling physicians to deliver industry-leading levels of patient care. Prior to Radiology Partners, he served as a key member of the DaVita IT leadership team.

In her new role as Vice President of Clinical Research, Ms. Green will oversee the clinical research arm of TOI and expand access to clinical trials for TOI patients. Ms. Green’s clinical research experience spans over 24 years across several different areas including data management, project management, clinical operations, and functional leadership. Most recently, she held roles at Labcorp Drug Development spearheading transformational initiatives for the conduct of clinical trials, including mobile health, decentralized clinical trials, and other study design innovations via data, technology, and process optimization. Ms. Green also led large multi-country based clinical operations teams during her tenure as Executive Director for Latin America from 2015–2017 and Executive Director for North America from 2011–2015.

TOI’s CEO Brad Hively commented, “TOI thrives on incredible leadership, and I couldn’t be more excited about these two seasoned leaders joining our team. The roles that Phil and Cristina fill are especially vital as we enhance our focus on research, technology, and health equity. I am confident that their contributions will help us advance even further.”

About The Oncology Institute

Founded in 2007, The Oncology Institute of Hope and Innovation (TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.6 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced healthcare organizations. With 80+ employed clinicians and more than 600 teammates in more than 50 clinic locations and growing, TOI is changing oncology for the better. For more information visit .

Contacts

Media

The Oncology Institute

Julie Korinke



(562) 735-3226 x 88806

Juan Lezama

(562) 374-8434

Investors

Solebury Trout

Maria Lycouris



EN
11/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ONCOLOGY INSTITUTE INC (THE)

 PRESS RELEASE

The Oncology Institute set to join the Russell 2000® and Russell 3000®...

The Oncology Institute set to join the Russell 2000® and Russell 3000® Indexes CERRITOS, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, today announced that it will join the Russell 2000® and Russell 3000® after the 2025 Russell indexes annual reconstitution, effective after the US market closes on June 27, according to a preliminary list of additions posted on May 23. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of April 30, ranking them by...

 PRESS RELEASE

The Oncology Institute Reports First Quarter 2025 Financial Results an...

The Oncology Institute Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance CERRITOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended March 31, 2025. Recent Operational Highlights Retail Pharmacy and Dispensary set fill records, contributing $49.3 million revenue and over $9 million in gross profit in Q1. The Pharmacy and Dispensary segment grew over 20% in th...

 PRESS RELEASE

The Oncology Institute Welcomes Dr. Jeff Langsam as Chief Clinical Off...

The Oncology Institute Welcomes Dr. Jeff Langsam as Chief Clinical Officer CERRITOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, announced today that Dr. Jeffrey Langsam will assume the role of enterprise Chief Clinical Officer effective May 13th, 2025. The CCO role will oversee therapeutics including pathway and procurement decisions, utilization management, and MSO practice clinical engagement. Dr. Langsam joins TOI from Cigna Healthcare, where he was the National Direct...

 PRESS RELEASE

The Oncology Institute to Participate at the B. Riley Securities 25th ...

The Oncology Institute to Participate at the B. Riley Securities 25th Annual Institutional Investor Conference CERRITOS, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, today announced that Dr. Daniel Virnich, Chief Executive Officer, and Rob Carter, Chief Financial Officer, will participate in B. Riley’s 25th Annual Institutional Investor Conference in Marina Del Rey, CA on May 21st, 2025. About The Oncology Institute Founded in 2007, TOI is advancing oncology by delivering...

 PRESS RELEASE

The Oncology Institute to Present at Upcoming ASCO Annual Meeting on H...

The Oncology Institute to Present at Upcoming ASCO Annual Meeting on High-Value Cancer Care Model Outcomes Showing Cost Savings and Lower Hospitalization Rates CERRITOS, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI)(“TOI”), one of the largest value-based oncology groups in the United States, announced today that it has been selected to present an abstract at the upcoming ASCO Annual Meeting further validating cost savings and reduced hospitalizations associated with its unique High-Value Cancer Care (HVCC) model*. The study shares new data supporting ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch